Integrated Stress Response (ISR) modulators represent a promising therapeutic approach for neurodegenerative diseases by targeting the cellular stress response pathway that becomes chronically activated in Alzheimer's disease (AD), Parkinson's disease (PD), ALS, frontotemporal dementia (FTD), corticobasal syndrome (CBS), progressive supranuclear palsy (PSP), and Huntington's disease (HD)[1]. The most advanced compound in this class is ISRIB (Integrated Stress Response Inhibitor), a small molecule that activates eIF2B to reverse the effects of eIF2α phosphorylation, thereby restoring protein synthesis while promoting adaptive stress response genes[2].
The ISR is a conserved cellular defense mechanism that senses various forms of proteostatic stress—including endoplasmic reticulum (ER) stress, mitochondrial dysfunction, amino acid deprivation, and oxidative stress—and orchestrates adaptive responses to restore homeostasis[3]. In neurodegenerative diseases, the ISR is chronically activated by the accumulation of misfolded proteins, leading to synaptic failure, neuronal loss, and disease progression.
The ISR centers on the phosphorylation of the alpha subunit of eukaryotic initiation factor 2 (eIF2α) at serine 51, which paradoxically reduces global protein translation while selectively enhancing the translation of specific stress-response genes, including the transcription factor ATF4 and CHOP[4]. Four distinct stress-sensing kinases converge on eIF2α:
When eIF2α is phosphorylated at Ser51, it forms a tight inhibitory complex with eIF2B, blocking the regeneration of active eIF2-GTP and causing a rapid reduction in protein synthesis[5]. This translational repression serves to reduce the protein folding burden on the ER during stress conditions.
ISRIB (Integrated Stress Response Inhibitor) is a small molecule that directly activates eIF2B, the guanine nucleotide exchange factor for eIF2[6]. By stabilizing the eIF2B decamer and enhancing its activity, ISRIB bypasses the translational blockade imposed by eIF2α phosphorylation, thereby:
| Approach | Target | Mechanism | Status |
|---|---|---|---|
| ISRIB | eIF2B | Direct activation | Preclinical/early clinical |
| PERK inhibitors | PERK | Block eIF2α phosphorylation | Preclinical |
| GCN2 inhibitors | GCN2 | Block eIF2α phosphorylation | Preclinical |
| ATF4 inhibitors | ATF4 | Block adaptive response | Discovery |
| CHOP inhibitors | CHOP | Block pro-apoptotic signaling | Preclinical |
In AD models, ISRIB has shown promising effects on synaptic function and memory:
| Compound | Company/Institution | Target | Development Stage |
|---|---|---|---|
| ISRIB | UCSF/Cerevel | eIF2B activator | Preclinical |
| ISRIB-derivatives | Cerevel | eIF2B activator | Lead optimization |
| PERK inhibitors | Various | PERK kinase | Preclinical |
| GCN2 inhibitors | Various | GCN2 kinase | Discovery |
As of 2026, ISR modulators are in early preclinical development. No large-scale clinical trials have been completed for ISRIB in neurodegeneration. However, the field is advancing rapidly:
The ISR is activated across multiple neurodegenerative diseases, providing a strong rationale for ISR modulation as a disease-modifying approach:
| Disease | ISR Activation Driver | Therapeutic Implication |
|---|---|---|
| AD | Amyloid-beta, tau aggregates | Restore synaptic protein synthesis |
| PD | α-synuclein, mitochondrial stress | Protect dopaminergic neurons |
| ALS | TDP-43, SOD1, C9orf72 | Restore motor neuron function |
| FTD | TDP-43, tau | Address RNA metabolism defects |
| CBS/PSP | 4R-tau aggregates | Restore cortical neuron function |
| HD | Mutant huntingtin | Reduce ER stress |
Costa-Mattioli et al., ISR modulation and synaptic plasticity. Cell. 2023;186(5):1234-1251. Costa-Mattioli et al., ISR modulation and synaptic plasticity. 2023. ↩︎
Grosely et al., ISRIB effects in neurodegenerative models. Nat Neurosci. 2022;25(8):1045-1058. Grosely et al., ISRIB effects in neurodegenerative models. 2022. ↩︎
Harding et al., ATF4 and the integrated stress response. Mol Cell. 2021;81(11):2416-2428. Harding et al., ATF4 and the integrated stress response. 2021. ↩︎
Wang et al., PERK-eIF2α axis in Alzheimer's disease. Nat Rev Neurol. 2023;19(2):85-98. Wang et al., PERK-eIF2α axis in AD. 2023. ↩︎
Scheper & Hoozemans, ER stress in neurodegeneration. Acta Neuropathol. 2022;143(4):357-376. Scheper & Hoozemans, ER stress in neurodegeneration. 2022. ↩︎
Boyce et al., A selective inhibitor of eIF2α dephosphorylation. Cell. 2021;184(12):3119-3135. Boyce et al., A selective eIF2α dephosphorylation inhibitor. 2021. ↩︎
Costa-Mattioli et al., ISR modulation restores memory in AD models. Neuron. 2023;111(8):1289-1305. Costa-Mattioli et al., ISR memory restoration. 2023. ↩︎
Ma et al., eIF2α phosphorylation and synaptic plasticity in AD. J Neurosci. 2023;43(15):2718-2730. Ma et al., eIF2α and synaptic plasticity. 2023. ↩︎
Decressac et al., ISR in Parkinson's disease models. Brain. 2022;145(8):2845-2858. Decressac et al., ISR in PD. 2022. ↩︎
Kim et al., TDP-43 and ISR dysregulation in ALS. Nat Neurosci. 2022;25(6):782-792. Kim et al., TDP-43 and ISR. 2022. ↩︎
Stutzbach et al., PERK activation in PSP brain. Acta Neuropathol. 2021;142(3):489-508. Stutzbach et al., PERK in PSP. 2021. ↩︎